Akoya Biosciences, Inc. Share Price

Equities

AKYA

US00974H1041

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 21:00:00 26/04/2024 BST 5-day change 1st Jan Change
3.8 USD -0.52% Intraday chart for Akoya Biosciences, Inc. 0.00% -22.13%
Sales 2024 * 116M 9.25B Sales 2025 * 137M 10.96B Capitalization 188M 15B
Net income 2024 * -41M -3.28B Net income 2025 * -26M -2.08B EV / Sales 2024 * 1.51 x
Net cash position 2024 * 12.67M 1.01B Net cash position 2025 * 14.68M 1.17B EV / Sales 2025 * 1.26 x
P/E ratio 2024 *
-4.53 x
P/E ratio 2025 *
-7.26 x
Employees 330
Yield 2024 *
-
Yield 2025 *
-
Free-Float 51.57%
More Fundamentals * Assessed data
Dynamic Chart
Akoya Biosciences Showcases Spatial Biology 2.0 Solutions At AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale CI
JPMorgan Adjusts Price Target on Akoya Biosciences to $10 From $12, Maintains Overweight Rating MT
UBS Adjusts Akoya Biosciences Price Target to $7.50 From $7, Maintains Buy Rating MT
Akoya Biosciences, Inc. Provides Revenue Guidance for the Full Year 2024 CI
Transcript : Akoya Biosciences, Inc., Q4 2023 Earnings Call, Mar 04, 2024
Earnings Flash (AKYA) AKOYA BIOSCIENCES Posts Q4 Revenue $26.5M, vs. Street Est of $26.1M MT
Akoya Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
North American Morning Briefing : Stock Futures -2- DJ
Transcript : Akoya Biosciences, Inc. - Special Call
Transcript : Akoya Biosciences, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:45 PM
Akoya Biosciences, Inc. Announces Board Changes CI
Akoya Biosciences Shares Jump on 2024 Outlook, Thermo Fisher Deal DJ
Akoya Biosciences Expects 20% Revenue Growth in 2024; Shares Gain Premarket MT
Akoya Biosciences Unveils Algorithm for Integration of Spatial, Single-Cell Data; Shares Jump Premarket MT
Akoya Biosciences Deploys the Maxfuse Algorithm Co-Developed by Dr. Garry Nolan and His Laboratory At Stanford University for Multiomic Integration of Spatial and Single-Cell Data on the Enable Medicine Platform CI
More news
1 day-0.52%
Current month-18.98%
1 month-18.98%
3 months-21.65%
6 months+21.41%
Current year-22.13%
More quotes
1 week
3.72
Extreme 3.72
4.00
1 month
3.72
Extreme 3.72
4.69
Current year
3.72
Extreme 3.72
6.31
1 year
3.04
Extreme 3.04
8.80
3 years
3.04
Extreme 3.04
23.44
5 years
3.04
Extreme 3.04
28.96
10 years
3.04
Extreme 3.04
28.96
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 30/06/17
Director of Finance/CFO 48 19/03/23
Chief Tech/Sci/R&D Officer - 25/10/21
Members of the board TitleAgeSince
Chairman 67 31/10/15
Director/Board Member 66 15/09/21
Director/Board Member 67 31/08/19
More insiders
Date Price Change Volume
26/04/24 3.8 -0.52% 93,172
25/04/24 3.82 +0.26% 88,258
24/04/24 3.81 0.00% 103,157
23/04/24 3.81 -2.31% 85,659
22/04/24 3.9 +2.63% 63,480

Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm

More quotes
Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery, clinical research, and diagnostics. It offers single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. It offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode Panels and PhenoCycler, PhenoImager Fusion and PhenoImager HT Instruments. Its PhenoCycler platform provides ultra-high parameter biomarker discovery, with the ability to analyze high-plex single-cell resolution across the entire tissue sample. Its PhenoImager platform enables researchers to visualize, analyze, quantify and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded (FFPE) tissue sections, and tissue microarrays (TMAs).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
3.8 USD
Average target price
9 USD
Spread / Average Target
+136.84%
Consensus